Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation The Chinese Atrial Fibrillation Registry Study
Background and Purpose-Reported rates of oral anticoagulation (OAC) use have been low among Chinese patients with atrial fibrillation (AF). With improved awareness, changing guidelines, this situation may be changing over time. We aimed to explore the current status and time trends of OAC use in Beijing. Methods-We used the data set from the Chinese Atrial Fibrillation Registry (CAFR), a prospective, multicenter, hospital-based registry study involving 20 tertiary and 12 nontertiary hospitals in Beijing. A total of 11496 patients with AF were enrolled from 2011 to 2014. Results-Seven thousand nine hundred seventy-seven eligible patients were included in this ancillary study. The proportions of OAC use were 36.5% (2268/6210), 28.5% (333/1168), and 21.4% (128/599) for patients with CHA(2)DS(2)-VASc scores >= 2, 1, and 0, respectively. Persistent AF, history of stroke/transient ischemic attack/peripheral embolism, diabetes mellitus, higher body mass index, and tertiary hospital management were factors positively associated with OAC use, whereas older age, previous bleeding, hypercholesterolemia, and established coronary artery disease were factors negatively associated with OAC use. Among patients with CHADS(2) scores >= 2 and CHA(2)DS(2)-VASc scores >= 2, the proportion of OAC use increased from 31.3% to 64.5% and 30.2% to 57.7%, respectively, from 2011 to 2014. Variation in OAC use was substantial among different hospitals. Conclusions-An improvement of OAC use among Chinese patients with AF in Beijing is observed in recent years although only 36.5% of patients with CHA(2)DS(2)-VASc score >= 2 received OAC. However, variations between different hospitals were large, suggesting that better education and awareness are needed to improve efforts for stroke prevention among AF patients.
基金:
Ministry of Science and Technology of the People's Republic of ChinaMinistry of Science and Technology, China [2013BAI09B02]; Beijing Municipal Commission of Science and Technology [ZYLX201302, D111100003011004, D131100002313001]; BMSBristol-Myers Squibb; PfizerPfizer; Johnson JohnsonJohnson & Johnson USA; BI; BayerBayer AG
第一作者机构:[1]Capital Med Univ, Beijing AnZhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, Beijing, Peoples R China;
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing AnZhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, Beijing, Peoples R China;[4]Capital Med Univ, Beijing AnZhen Hosp, 2 AnZhen Rd, Beijing 100029, Peoples R China
推荐引用方式(GB/T 7714):
Chang San-Shuai,Dong Jian-Zeng,Ma Chang-Sheng,et al.Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation The Chinese Atrial Fibrillation Registry Study[J].STROKE.2016,47(7):1803-1810.doi:10.1161/STROKEAHA.116.012988.
APA:
Chang, San-Shuai,Dong, Jian-Zeng,Ma, Chang-Sheng,Du, Xin,Wu, Jia-Hui...&Lip, Gregory Y. H..(2016).Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation The Chinese Atrial Fibrillation Registry Study.STROKE,47,(7)
MLA:
Chang, San-Shuai,et al."Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation The Chinese Atrial Fibrillation Registry Study".STROKE 47..7(2016):1803-1810